Get the Stockscreener App
0.00
100.00%
-70.50
Metsera Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$70.50
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$7.43B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$83.86
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
0.00 | 7.43B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | Wells Fargo | Overweight |
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
View All
Metsera Inc Stock (MTSR) Latest News
Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next - ts2.tech
Metsera Inc Stock Analysis and ForecastStraddle and Strangle Trades & Outstanding Profit Strategies - earlytimes.in
Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks - ts2.tech
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025) - ts2.tech
Pfizer : November Social Media Round-Up—Third-Quarter Earnings, Metsera Acquisition, and MoreUpdates & StatementsAlbert BourlaArtificial IntelligenceBusinessCancerHealth Equity - marketscreener.com
November Social Media Round-Up—Third-Quarter Earnings, Metsera Acquisition, and More - Pfizer
Will Metsera Inc. stock benefit from automationJuly 2025 Update & High Accuracy Swing Entry Alerts - Newser
Why Metsera Inc. stock is seen as undervaluedJuly 2025 Market Mood & AI Driven Stock Price Forecasts - Newser
Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts - ts2.tech
Pfizer Stock Price ForecastPFE Shares Surges Toward $30 With Metsera Deal & $7.2B Cost Cuts Drive 2026 Recovery - TradingNEWS
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield - ts2.tech
Pfizer: The Pharma Giant To Buy Right Now (NYSE:PFE) - Seeking Alpha
Aug PostEarnings: Will Metsera Inc. stock reach Wall Street targetsExit Point & Daily Volume Surge Signals - BỘ NỘI VỤ
Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle - MSN
Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating - MSN
Key facts: Novo Nordisk shares rise; partners in UAE; bids for Metsera - TradingView
Is Pfizer Stock A Buy After It Clinches The $10 Billion Takeover Of Metsera? - Investor's Business Daily
PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge - ts2.tech
Pfizer’s CFO on building a post-Covid future and how it won the fight for Metsera - Sherwood News
No plane sailing for Novo Nordisk - MarketScreener
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend - ts2.tech
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further - MSN
Promising Mid Cap Stocks Worth WatchingNovember 20th - MarketBeat
Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors - ts2.tech
Can Metsera Inc. stock sustain free cash flow growthJuly 2025 Rallies & Intraday High Probability Alerts - newser.com
Promising Mid Cap Stocks To ConsiderNovember 17th - MarketBeat
Top Mid Cap Stocks To Follow NowNovember 19th - MarketBeat
Pfizer exec challenges Novo Nordisk, Eli Lilly after Metsera win - medwatch.com
Tools to monitor Metsera Inc. recovery probabilityQuarterly Profit Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Metsera Inc. stock a safe investment in uncertain marketsJuly 2025 Momentum & AI Enhanced Execution Alerts - newser.com
How to build a custom watchlist for Metsera Inc.Trade Exit Report & Free AI Powered Buy and Sell Recommendations - newser.com
How Metsera Inc. stock performs in stagflationTrade Risk Assessment & Long Hold Capital Preservation Plans - newser.com
Jefferies 25: Pfizer Still Hungry For Anti-Obesity Deals After Metsera - Citeline News & Insights
Best Mid Cap Stocks To Add to Your WatchlistNovember 14th - MarketBeat
Pfizer intends to raise $5 billion to finance the deal with Metsera - AKM.RU
Is Metsera Inc. forming a bottoming baseJuly 2025 Final Week & Weekly Top Performers Watchlists - newser.com
Pfizer to seek oral obesity drugs globally after Metsera deal- CEO - Investing.com
Why Metsera Inc. stock appeals to analystsQuarterly Profit Review & Fast Exit and Entry Strategy Plans - newser.com
Pfizer (PFE) Plans $5 Billion Bond Issuance to Fund Metsera Acqu - GuruFocus
(11/19/25) PFE: The Winner in the Metsera Bidding War - moneyshow.com
PFE- The Winner in the Metsera Bidding War - Yahoo Finance
Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market - AOL.com
Pfizer sells US$6bn of bonds for Metsera acquisition - IFR Asia
Pfizer Kicks Off US Dollar Bond Sale to Help Fund Metsera Deal - Bloomberg.com
Pfizer reportedly seeking $5B bond sale for Metsera acquisition - MSN
Pfizer (PFE) Plans $5B Bond Offering to Support Metsera Acquisition - GuruFocus
Pfizer seeking $5B bond sale for Metsera deal (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) Taps Bond Market for $5 Billion to Fund Metsera Acquisition - TipRanks
Pfizer Seeking at Least $5 Billion in Bond Sale for Metsera Deal, Bloomberg Reports - MarketScreener
Stock Watch: Addressing Pfizer’s Pandemic Revenue Replacement - Citeline News & Insights
Metsera Inc. stock chart pattern explainedPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - newser.com
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):